Newer second generation supraglottic airway devices may perform differently in vivo due to material and design modifications. We compared performance characteristics of the Ambu® AuraGain™ and LMA Supreme™ Second Seal™ in 100 spontaneously breathing anaesthetised patients in this randomised controlled study. We studied oropharyngeal leak pressures (OLP) (primary outcome) and secondarily, ease of insertion, success rates, haemodynamic response, time to insertion, and complications of usage. We found no significant difference in OLP between the AuraGain versus the LMA Supreme, mean (standard deviation, SD) 24.1 (7.4) versus 23.6 (6.2) cmH 2 O, P=0.720. First-attempt placement rates of the AuraGain were comparable to the LMA Supreme, 43/50 (86%) versus 39/50 (78%), P=0.906, with an overall 98% insertion success rate for the AuraGain and 88% for the LMA Supreme after three attempts, P=0.112. However, the AuraGain was deemed subjectively harder to insert, with only 24/50 (48%) versus 37/50 (74%) of AuraGain insertions being scored 1 = easy (on a 5 point scale), P=0.013, and also took longer to insert, 33.4 (SD 10.9) versus 27.3 (SD 11.4) seconds, P=0.010. The AuraGain needed a smaller volume of air (16.4 [SD 6.8] versus 23.0 [SD 7.4] ml, P <0.001) to attain intracuff pressures of 60 cmH 2 O, facilitated more successful gastric tube insertion (100% versus 90.9%, P=0.046), and had significantly decreased sore throat incidence (10% versus 38%, P=0.020). One AuraGain and six LMA Supremes failed to be placed within the stipulated 120 seconds trial definition of 'success'; these patients had risk factors for failed supraglottic insertion. In conclusion, both devices had similar OLPs and performed satisfactorily. However, the AuraGain resulted in less postoperative sore throat despite being harder to, and taking longer to, insert.
Introduction
The Ambu® AuraGain™ (Ambu A/S, Ballerup, Denmark) is a new anatomically curved, single-use supraglottic airway device launched in June 2014, that features an integrated gastric access port and direct intubation capability using a standard endotracheal tube ideally guided by a flexible videoscope. These three features (airway maintenance, managing gastric contents and intubation capability) herald the third generation supraglottic airway devices aimed at improving patient safety and decreasing morbidity whilst tried and tested products undergo product modifications. One such example is the Laryngeal Mask Airway Supreme™ with its Second Seal™ (LMA Teleflex, Athlone, Co Westmeath, Ireland), clinically introduced in 2013, designed to reduce the risk of gastric insufflation during ventilation, provide a passive conduit for unexpected regurgitation, and allow active suctioning of gastric contents. We aimed to assess the clinical performance of the new AuraGain and LMA Supreme Second Seal in spontaneously breathing anaesthetised patients.
Our primary outcome measure was oropharyngeal leak pressure. We also studied the relative ease of insertion, success rates, haemodynamic response, time to insertion and complications of usage as secondary outcome measures.
Methods
After approval from the hospital's Institutional Review Board (UMREC Number: 20148-425) and prospective trial registration on the Australian New Zealand Clinical Trials Registry (Trial Number: ACTRN12614001290684), we recruited a total of 100 patients, scheduled for elective surgical procedures under general anaesthesia, who were amenable to supraglottic airway management in our tertiary hospital. We excluded patients of American Society of Anesthesiologists (ASA) physical status 4, the morbidly obese (body mass index [BMI] >40 kg/m 2 ), those at high risk of regurgitation or aspiration (e.g. symptomatic gastrooesophageal reflux, hiatus hernia), or with respiratory tract pathology (e.g. preoperative sore throat).
Patients were randomised into two groups: 'Ambu AuraGain' or 'LMA Supreme' using a computer-generated random number table. After recruitment, the enrolling investigators opened sealed opaque envelopes that concealed group allocation. Patients were blinded to their group allocation. The size of the airway was chosen in accordance with the manufacturers' recommendations.
Patients were not premedicated. They were positioned supine on the operating table, with the head resting on a gel head ring. Standard monitoring was instituted before induction of anaesthesia, i.e. pulse oximetry, electrocardiograph and non-invasive blood pressure. Preoxygenation was carried out with high flow oxygen for three minutes prior to induction of anaesthesia with intravenous fentanyl 1-2 µg/kg and propofol 2-3 mg/kg.
The Ambu AuraGain and LMA Supreme were lubricated and prepared according to the manufacturers' recommendations. The airway device was inserted when the jaw was sufficiently slack. The cuff of each device was then inflated with air to attain a cuff pressure of 60 cmH 2 O as measured with a handheld aneroid manometer (Portex® Pressure Gauge; Smiths Medical Intl Ltd, Kent, UK). The total volume of air needed to do this was determined by inflating each device with an initial amount of 25 ml, after which the manometer was connected to ascertain the cuff pressure, with subsequent addition or withdrawal of air in aliquots of 1-3 ml to achieve the final pressure of 60 cmH 2 O. The appearance of the first square end-tidal carbon dioxide (ETCO 2 ) trace denoted successful establishment of effective ventilation. Otherwise, the device was completely removed for another insertion attempt. Three insertion attempts were allowed. Each 'attempt' was defined as reinsertion of the airway device into the mouth. We defined 'insertion failure' of the device as one comprising greater than three unsuccessful attempts or if the entire process of insertion exceeded 120 seconds. This included the time the airway device was removed from the mouth and any bag-mask ventilation in between. In case of failure of either device, the airway was secured according to the decision of the attending anaesthetist.
Once the airway device was in place, the tube was fixed by taping over the patient's cheek. A gel plug was placed in the proximal one centimetre of the gastric drain outlet and the suprasternal notch test was done to confirm placement (gently tapping the suprasternal notch causes the gel to pulsate, confirming the tip location behind the cricoid cartilage). For both airway devices, a 14 French gauge gastric tube was inserted through the gastric drain outlet.
These gastric tubes were pre-lubricated with a water-soluble lubricant. Ease of insertion was graded 1 to 3 (1 = easy, 2 = difficult, 3 = impossible). Time for insertion of the gastric catheter was also noted. Confirmation of correct placement of the gastric catheter was through detection of injected air by auscultation of the epigastrium, and aspiration of gastric contents. Gastric decompression was performed and the amount of gastric fluid aspirated was noted. All the patients had a minimum six hours fasting time.
Oropharyngeal leak pressure (OLP) was measured after closing the adjustable pressure-limiting valve with a fresh gas flow of three litres/minute, noting the airway pressure at equilibrium or when there was audible air leak from the throat. The epigastrium was also auscultated when measuring the OLP to detect any air entrainment in the stomach.
We recorded the number of insertion attempts and time to establish effective ventilation (interval from when the AuraGain or LMA Supreme entered the mouth to first ETCO 2 trace); the ease of insertion of the airway, subjectively assessed on a five-point scale (1 = easy, 2 = acceptable, 3 = difficult, 4 = very difficult, 5 = impossible); blood pressure and heart rate every minute for the first five minutes from induction of anaesthesia; manoeuvres required to optimise positioning or ventilation with the airway devices: adjusting head and neck position, depth of insertion, applying jaw lift, and changing device size.
Maintenance of anaesthesia was achieved with sevoflurane, minimum alveolar concentration 1-2 in an oxygen-air mixture. The airway device was removed when the patients opened their eyes and obeyed commands. The airway device was then inspected for presence of visible blood. Forty-five minutes later, patients were assessed by a blinded independent observer for postoperative sore throat, dysphonia or dysphagia.
All airway insertions were performed by experienced staff anaesthesiologists with more than ten years experience with supraglottic airway management, who had performed at least five clinical AuraGain insertions prior to trial commencement. Contemporaneous data collection of airway insertion times, ventilatory parameters and complications of placement (desaturation <95%, gross regurgitation or aspiration [defined as fluid in the ventilation tube], bronchospasm, or mucosal, lip, tongue or dental injury) were done by an unblinded observer who was not involved in the study.
Statistical analysis
Our primary comparison measure was OLP. Sample size was based on previous studies we conducted involving LMA Supreme insertions that demonstrated a mean (standard deviation, SD) OLP of 26 (5) cmH 2 O 1 . In order to detect a difference of 10%, prospective power analysis at 80% power and 0.05 level of significance (two-tailed) showed that a sample size of 47 patients would be required. Therefore, we recruited 50 patients per group to account for dropouts and protocol breaches. We used the Student's t-test to analyse insertion times and other parametric data; Mann-Whitney U test for Mallampati scores and other non-parametric data; Fisher's exact test for comparison of side-effects, and the general linear model for repeated measures for haemodynamic variables. The 95% confidence interval for the insertion success rate is calculated according to the formula in Pandit's paper 2 . All statistical analyses were performed using SPSS 22.0™ (SPSS Inc., Chicago, IL, USA) software. A P value of <0.05 was deemed statistically significant.
Results
One hundred and forty-seven patients were approached and assessed for eligibility; one hundred patients were eventually recruited and randomised ( Figure 1 ). There was no significant difference in patients' baseline demographics, airway anthropometric features, or in type or duration of surgery (Table 1) .
We found no significant difference in the primary outcome measure of OLP between the two airway devices, AuraGain 24.1 (SD 7.4) versus 23.6 (SD 6.2) cmH 2 subjectively harder to insert, with only 24/50 (48%) of AuraGain insertions being scored 1 = easy (on a five point scale), versus 37/50 (74%) for the LMA Supreme, P=0.013. Nonetheless, there were no significant differences in the need for repositioning nor optimisation manoeuvres required to enable adequate and successful ventilation ( Table 2) .
The AuraGain needed a smaller volume of air (16.4 [SD 6.8] versus 23.0 [SD 7.4] ml, P <0.001) to attain a manometric intracuff pressure of 60 cmH 2 O, and took a mean of six seconds longer to obtain the first capnograph trace (from insertion into mouth) compared to the LMA Supreme, 33.4 (SD 10.9) versus 27.3 (SD 11.4) seconds, P=0.010. Passage of the gastric drain tube was easier and more successful with the AuraGain compared to the LMA Supreme, 100% versus 90.9%, P=0.046. The time taken to insert the gastric tube and volume of gastric aspirate obtained after insertion of the gastric tubes did not differ between devices. Air leak occurrence into the stomach was not significantly different either (Table 3) . Haemodynamic changes, i.e. mean arterial pressure (P=0.732) and heart rate (P=0.631) associated with airway device placement was comparable between groups using the general linear model for repeated measurements (Table 4) . One AuraGain and six LMA Supremes failed to be placed within the stipulated 120 seconds trial definition of 'success', and these patients were intubated with an endotracheal tube. The demographic data of patients with failed supraglottic insertion is shown in Table 5 .
We found that patients in the AuraGain group had a significantly decreased incidence of sore throat: 10% versus 38% in the LMA Supreme group, P=0.020. Transient oxygen desaturation to less than 95% (that was easily rectified by head/neck repositioning), difficulty in ventilation (which abated after the second insertion attempt), minor lip and mucosal injury, dysphonia and dysphagia were not significantly different between groups ( Table 2) . No one experienced regurgitation, aspiration, bronchospasm, tongue trauma or dental injury in this study.
Discussion
In spontaneously breathing anaesthetised patients, we found the newer Ambu AuraGain yielded similar OLP to the LMA Supreme, required a smaller volume of air to attain intracuff pressures of 60 cmH 2 O, facilitated easier orogastric tube insertion and resulted in significantly less sore throat. The insertion/placement of the AuraGain however was qualitatively harder and took longer, despite having similar first attempt (86% versus 78%) and overall (three attempts, 98% versus 88%) insertion success rates when compared to the LMA Supreme. The clinically higher insertion rates with the AuraGain (albeit not statistically significant) are somewhat surprising, given that the AuraGain is a newer product on the market and users had more prior experience with the LMA Supreme.
Of the subjective five-point scale used, 74% of LMA Supreme insertions were rated as 1 (easy), 9% scored 2 (acceptable) while 2% were rated 3 (difficult to insert). On the other hand, only 48% of AuraGain insertions were scored as easy, 40% were scored as acceptable and 12% as difficult. These are observational findings and the subjective insertion difficulties could perhaps be accounted for by differences in design and materials. Our clinical study corroborates the findings of a recent cadaveric study 3 whereby investigators found the firm tip of the AuraGain to be less pliable and did not bend easily toward the hypopharynx after hitting the posterior pharyngeal wall. They solved this by inserting the device by lateral rotation inside the mouth. Additionally, we found that in our predominantly Asian population of smaller build and with smaller mouth opening (there were no Caucasians in this study), we found the bulky posterior curvature of the AuraGain and its slightly larger cuff (designed to increase its seal pressure) subjectively harder to manoeuvre into the oral cavity. This was solved by ensuring the totally deflated cuff was well-lubricated and inserting the device laterally via a paramedian or side-sweeping technique in the mouth towards the hard palate in the midline. As a result, inserting the AuraGain took a mean six seconds longer.
The six insertion failures we experienced with the LMA Supreme are most likely due to repeated malposition of the tip into the airway. This phenomenon also occurred in fresh cadavers, where the LMA Supreme was easily advanced into the hypopharynx (compared to the AuraGain or i-gel® [Intersurgical Australia Pty Ltd, Matraville, NSW] supraglottic airway device) but the irregular tip of the LMA Supreme New Cuff or SoftSeal often collided or impacted with the arytenoids, causing misplacement into the glottis 3 . All the incidences of failure to insert an LMA Supreme occurred in patients who had one or more features of a difficult airway such as shortened thyromental distance, reduced sternomental distance, reduced inter-incisor distance, limited head/neck movement and inability to prognath the jaw ( Table 5 ). This correlates with a study by Saito et al that showed two out of four risk factors for difficult ventilation with supraglottic airways are short thyromental distance and limited neck movement 4 . Despite the lateral placement of the gastric drain tube port (existing at a 20 degree angle from the midline) of the AuraGain, the passage of a large bore gastric tube into the oesophagus was rated easier than for the LMA Supreme in our clinical study. This observational finding echoes the results of Lopez et al 3 in cadavers, suggesting that once in place, the tip of the gastric channel is properly aligned with the oesophagus allowing effective venting of any gastric contents. Significant differences in ease of insertion of the gastric tube between the LMA Supreme and other supraglottic airways like the i-gel have been previously reported in anaesthetised patients with neuromuscular blockade 1 and without 5 . These findings are most probably related to the narrower and less slippery surface of the i-gel channel.
Haemodynamic parameters at insertion were comparable for both supraglottic airway devices. During maintenance of anaesthesia over a mean surgical duration of 80 minutes, both devices performed well with none requiring airway manipulation to optimise ventilation during this phase. Postoperative follow-up revealed a significantly reduced incidence of sore throat in patients using the AuraGain (10% versus 38%, P=0.020). Inherent differences in material could account for this observational finding, as the AuraGain's thinner, softer cuff was able to deliver high seal pressures despite requiring a significantly less volume of air to attain a manometric cuff pressure of 60 cmH 2 O compared to the LMA Supreme. The resultant different pressure on surrounding laryngeal tissues and degree of dynamic tissue distortion are consequently different 6 . We found the higher incidence of insertion failure and sore throat with the newer LMA Supreme slightly atypical as previous institutional data had shown <10% sore throat with the older versions of the LMA Supreme [8] [9] and Ambu laryngeal mask [10] [11] . A possible reason for the higher sore throat incidence could be the irregular larger tip of the LMA Supreme Second Seal cuff that causes it to collide with the arytenoids 3 . This has implications for users preparing the device whereby extra vigilance and attention should be accorded to ensure that the tip and bowl of the cuff of the LMA Supreme is well lubricated, totally deflated and devoid of irregular edges prior to insertion. A recent editorial 12 expounded that over time, as existing airway devices undergo product modification mainly to improve their efficacy and safety, clinicians may sometimes find these to be inferior to the model before modifications; hence they should be ready to redo studies on the modified devices, and it would be prudent to be careful in using a newly modified airway device before gaining device-specific proficiency or mastering some tips and tricks.
Our study has a few limitations. We did not use fibreoptic bronchoscopy to assess the anatomical position of the AuraGain and LMA Supreme in relation to the vocal cords. This reflects our daily clinical practice, which is limited by time, resources and high surgical turnover. Others had previously demonstrated that the AuraGain provided better fibreoptic views of the larynx with less epiglottic downfolding than the LMA Supreme in children 7 but data from prospective trials in adults are still needed. This study was also powered to a minimum difference of 10% in OLP and as such, we cannot exclude any difference of less than 10% between devices. Additionally, in evaluating the performance of the two airway devices, about 30 multiple simultaneous subjective comparisons were made (despite having sufficient power only for the primary outcome), therefore all other P values, both significant and non-significant, should be interpreted with caution.
However, our study provides reassuring data that despite being a relatively newer device on the market, insertion success rates of the AuraGain remain high in the hands of relatively novice users compared to the LMA Supreme. Additionally, this study was undertaken in patients without neuromuscular blockade, which could otherwise have further enhanced insertion success by mitigating airway reflexes.
In conclusion, this study has demonstrated satisfactory performance of the new AuraGain in spontaneously breathing anaesthetised adults where it achieved comparable seal pressures (primary outcome) in the range of that obtained with LMA Supreme. As a secondary outcome, the AuraGain performed better than the LMA Supreme in allowing easier gastric access with a large bore gastric tube and was significantly associated with less sore throat. The combination of these features in a single device with less pharyngeal morbidity offers a promising alternative for airway management in challenging patients.
